A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)

Launched by UNIVERSITY OF ZURICH · Feb 26, 2013

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• • Inclusion criteria: •Women, aged \> 18 to \< 35 years
• • Having severe anorexia nervosa (AN) (DSM-IV-R) for \> 12 months before screening
• • Presenting with very low bone mineral density (defined as Z-Score \< -2.5 or T-Score \< -2.5 if available) of at least one of the assessed localizations (lumbar spine L1 - L4, total hip, femoral neck) without any previous fragility fracture
• • or low bone mineral density (defined as Z-Score \< -1.5 or T-Score \< -1.5 if available) of at least one of the assessed localizations (lumbar spine L1 - L4, total hip, femoral neck) and at least one previous fragility fracture
• • In- and out-patients of the Centre for Eating Disorders at the Clinic for Psychiatry and Psychotherapy of the University Hospital of Zurich.
• • Exclusion criteria: Metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism, osteomalacia, Paget's disease of bone), pre-existing hypercalcemia, severe renal impairment (GFR \< 30 ml/min), prior external beam or implant radiation therapy to the skeleton, skeletal malignancies or bone metastases, any unknown elevation of serum alkaline phosphatase, severe psychiatric diseases other than AN, drug addiction, HIV positive patients, pregnancy, open epiphyses
• • •Incapacity to understand the aims of the study or patients not willing to collaborate.